Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gaush MeditechHKSE:02407 -0.43%60 5-Year Yield-on-Cost % is 0.00 as of Aug. 25, 2026. GuruFocus rates HKSE:02407 with a GF Score™ of 60/100 and a GF Value™ of HK$13.69 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 315 Medical Devices & Instruments companies, Gaush Meditech ranks worse than 317460% on this metric.
Gaush Meditech's yield on cost for the quarter that ended in Dec. 2025 was 0.00.
The historical rank and industry rank for Gaush Meditech's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 7 years, Gaush Meditech's highest Yield on Cost was 21.18. The lowest was 3.76. And the median was 12.08.
HKSE:02407's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.43 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Gaush Meditech 5-Year Yield-on-Cost % Related Terms
HKSE:02407 vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Gaush Meditech's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gaush Meditech 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gaush Meditech's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Gaush Meditech's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Gaush Meditech is calculated as
Gaush Meditech (HKSE:02407) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 25, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Gaush Meditech and its competitors. Over the past decade, Gaush Meditech's 5-Year Yield-on-Cost % has ranged from 3.76 to 21.18. According to the industry distribution chart, Gaush Meditech ranks #999999 out of 315 companies in the Medical Devices & Instruments industry.
Is Gaush Meditech's 5-Year Yield-on-Cost % too high?
Gaush Meditech's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 3.76 to a high of 21.18. Based on the distribution chart, Gaush Meditech ranks #999999 out of 315 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Gaush Meditech has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gaush Meditech's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gaush Meditech ranks #999999 out of 315 companies for 5-Year Yield-on-Cost %. This places Gaush Meditech in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.43. Historically, Gaush Meditech's own 5-Year Yield-on-Cost % has ranged from 3.76 to 21.18 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.43, based on 315 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Gaush Meditech and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gaush Meditech's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gaush Meditech stock overvalued right now?
Based on GuruFocus' analysis, Gaush Meditech (HKSE:02407) is currently considered Possible Value Trap. The stock's GF Value™ is HK$13.69, compared to a current price of HK$4.67 — trading 65.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Gaush Meditech's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Gaush Meditech (HKSE:02407), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gaush Meditech (HKSE:02407) Overvalued in 2026?
Based on GuruFocus' analysis, Gaush Meditech stock appears to be undervalued.
The current stock price of HK$4.67 is trading 65.9% below its estimated GF Value™ of HK$13.69.
GuruFocus considers Gaush Meditech to be Possible Value Trap.
Key valuation signals for HKSE:02407:
5-Year Yield-on-Cost %: 0.00
GF Value™: HK$13.69 vs. price of HK$4.67 (65.9% below fair value)
No single metric tells the full story. See the HKSE:02407 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gaush Meditech Ltd is a provider of a broad spectrum of manufacture and sale ophthalmic medical devices and provision of technical services. The segments of the company include Proprietary products segment that derives maximum revenue, develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; Technical services segment provides warranty services, maintenance services and other related consumables; and Others segment.
60GF Score
Get the complete analysis for HKSE:02407
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02407 has been successfully added to your 
